Respiratory Tract Infection Treatment Market is expected to reach US$ 69.13 billion by 2031

Antibiotics Segment to Dominate Global Respiratory Tract Infection Treatment Market During 2021–2031

According to our new research study on "Global Respiratory Tract Infection Treatment Market Size and Forecast (2021–2031), Global and Regional Share, Trend, and Growth Opportunity Analysis," the market was valued at US$ 43.6 billion in 2023 and is expected to reach US$ 69.13 billion by 2031; it is anticipated to register a CAGR of 5.93% during 2023–2031. The global respiratory tract infection treatment market report emphasizes the key factors driving the market and showcases the developments of prominent players. Key factors driving the global respiratory tract infection treatment market growth include the rising cases of respiratory infections and increasing awareness related to respiratory tract infections. However, the lack of research focused on respiratory therapeutics hinders the market growth.

In recent years, there has been a notable increase in awareness about respiratory tract infection, driven by the rising prevalence of respiratory diseases such as LRTI and URTI. Governments worldwide are actively involved in promoting public health initiatives and guidelines to educate the population about the prevention and management of respiratory infections. The increasing prevalence of chronic respiratory diseases such as asthma, pulmonary hypertension, chronic pulmonary fibrosis, and occupational lung diseases is boosting the overall respiratory infection treatment market growth. For instance, asthma and chronic obstructive pulmonary disease are common respiratory diseases characterized by variable airflow limitation and airway hyperresponsiveness. Additionally, the increase in respiratory diseases, technological advances in drug development, and the easy availability of generic drugs will push the expansion of the treatment field of upper respiratory tract infections in the coming years.

Respiratory Tract Infection Treatment Market

Rising demand for over-the-counter drugs is another driving factor. Patients with colds and coughs often avoid visiting healthcare professionals because the infection can be self-treated with over-the-counter medications. Nasal decongestants such as Afrin (oxymetazoline nasal), Neo-Synephrine (phenylephrine nasal), and Sudafed PE (phenylephrine oral) are some of the over-the-counter drugs that help unclog congested nasal. Hence, the rising demand for over-the-counter (OTC) drugs is expected to have a positive impact on the growth of the global upper respiratory tract infection treatment market during the forecast period.

Furthermore, government efforts related to respiratory infection have led to improved healthcare practices, early detection, and timely treatment of respiratory tract infections. Thus, the increasing awareness related to respiratory tract infections drives the global respiratory tract infection treatment market growth. Further, the advent of antiviral treatment for respiratory diseases is expected to bring new global respiratory tract infection treatment market trends in the coming years.

Abbott Laboratories, AstraZeneca plc, Alembic Pharmaceuticals Ltd., Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Novartis AG, F. Hoffmann-La Roche AG, Sanofi S.A., Merck & Co, Cipla are among the prominent players profiled in the global respiratory tract infection treatment market report. In addition, several other players were studied and analyzed to get a holistic view of the market and its ecosystem. The global respiratory tract infection treatment market forecast can help stakeholders plan their growth strategies.

• In April 2022, Pfizer Inc. and ReViral Ltd entered into a definitive agreement under which Pfizer will acquire ReViral, a privately held, clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel antiviral therapeutics that target respiratory syncytial virus (RSV).
• In December 2023, AstraZeneca company entered into a definitive agreement to acquire Icosavax, Inc., a US-based clinical-stage biopharmaceutical company focused on developing differentiated, high-potential vaccines, protein virus-like particle (VLP) platform. The acquisition was based on AstraZeneca’s expertise in respiratory syncytial virus (RSV), strengthening AstraZeneca’s Vaccines & Immune Therapies late-stage pipeline with Icosavax’s lead investigational vaccine candidate, IVX-A12. IVX-A12 is a potential first-in- class, Phase III-ready, combination protein VLP vaccine which targets both RSV and human metapneumovirus (hMPV.
• In May 2023, GSK plc received US Food and Drug Administration (FDA) approval Arexvy (respiratory syncytial virus vaccine, adjuvanted) for the prevention of lower respiratory tract disease (LRTD) caused by RSV in 60 years of age and older population. This is the first RSV vaccine for older adults to be approved globally.

The global respiratory tract infection treatment market analysis is based on the following segments: drugs, disease indication, route of administration, age group, and distribution channel. Based on drug, the market is differentiated into antibiotics, NSAIDs, cough suppressants, nasal decongestants, and others. The antibiotics segment held the largest global respiratory tract infection treatment market share in 2023 and the same is anticipated to register the highest CAGR during 2023–2031. By disease indication, the market is bifurcated into upper respiratory tract infection and lower respiratory tract infection. The lower respiratory tract infection segment held a larger market share in 2023, and it is anticipated to register a higher CAGR from 2023 to 2031.

In terms of route of administration, the market is differentiated into oral and parenteral. The oral segment held a larger global respiratory tract infection treatment market share, and it is anticipated to register a higher CAGR during 2023–2031. Based on age group, the global respiratory tract infection treatment market is classified into pediatric and adult. The pediatrics segment is anticipated to register a higher CAGR during 2023–2031. Based on distribution channel, the global respiratory tract infection treatment market is segmented into hospital pharmacies, online pharmacies, and retail pharmacies. The hospital pharmacies segment is anticipated to account for a significant market share during 2023–2031.

Contact Us
 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com